Compare Costco Wholesale Corporation (COST) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Neurocrine Biosciences Inc — how do they compare? Costco Wholesale Corporation trades at $946 (market cap $417.54B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Costco Wholesale Corporation is far larger — about 28.6× Neurocrine Biosciences Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Neurocrine Biosciences Inc for 23 Days on average.
| COST | NBIX | |
|---|---|---|
Market Cap | $417.54B | $14.60B |
Volume | 1,767,362 | 1,075,694 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $185.50 |
52-Week Low | $849.63 | $123.10 |
Typical Hold Time | 132 Days | 23 Days |
Enterprise Value | $404.81B | $14.61B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $942.25, up 0.7% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year, and fiscal 2025 revenue reached $275.24 billion with net income of $8.10 billion. Analyst consensus is strongly bullish with a $1,090 price target, though valuation ratios like P/E of 45.39 are elevated.
The outlook remains positive due to membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is solid with recent beats, supporting the buy-rated sentiment, yet any market pullback could present a better entry point for long-term investors.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
